Compare PCSA & TOMZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCSA | TOMZ |
|---|---|---|
| Founded | 2011 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Commercial Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.7M | 17.5M |
| IPO Year | N/A | N/A |
| Metric | PCSA | TOMZ |
|---|---|---|
| Price | $0.27 | $0.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $1.00 | ★ $3.50 |
| AVG Volume (30 Days) | ★ 1.1M | 18.0K |
| Earning Date | 11-06-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $5,688,341.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $68.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.15 | $0.63 |
| 52 Week High | $1.50 | $1.50 |
| Indicator | PCSA | TOMZ |
|---|---|---|
| Relative Strength Index (RSI) | 48.05 | 49.59 |
| Support Level | $0.27 | $0.78 |
| Resistance Level | $0.30 | $0.83 |
| Average True Range (ATR) | 0.02 | 0.03 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 62.34 | 72.16 |
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
TOMI Environmental Solutions Inc is a leader in bacteria decontamination and infectious disease control, offering environmentally friendly solutions for indoor air and surface disinfection and decontamination. Its flagship product, SteraMist, uses patented and registered Binary Ionization Technology (BIT) to deliver a low-percentage (7.8%) hydrogen peroxide-based fog or mist to affect all indoor environments and surface areas. Its product portfolio includes The SteraPak, The Surface Unit, The Transport, The NV+, The Environment System, SteraMist Integrated System, BIT Solution, and Custom Engineered System.